Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income: 2010-2025

Historic Net Income for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Net Income rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 156.81%. This contributed to the annual value of $102.8 million for FY2024, which is 108.17% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Net Income is $40.1 million, which was up 69.84% from $23.6 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Net Income registered a high of $391.3 million during Q2 2021, and its lowest value of -$1.1 billion during Q2 2023.
  • Its 3-year average for Net Income is -$102.6 million, with a median of $3.6 million in 2024.
  • In the last 5 years, Ironwood Pharmaceuticals' Net Income tumbled by 3,038.30% in 2023 and then surged by 2,844.07% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Income (Quarterly) stood at $41.4 million in 2021, then rose by 18.16% to $48.9 million in 2022, then slumped by 567.15% to -$228.3 million in 2023, then soared by 145.63% to $104.2 million in 2024, then surged by 999.29% to $40.1 million in 2025.
  • Its Net Income stands at $40.1 million for Q3 2025, versus $23.6 million for Q2 2025 and -$37.4 million for Q1 2025.